SEIZURE - Nursing Case Study

Pathophysiology

• Primary mechanism: Seizures result from abnormal electrical activity in the brain due to hyperexcitability of neurons. This can occur when there's an imbalance between excitatory neurotransmitters, like glutamate, and inhibitory neurotransmitters, such as GABA, leading to excessive neuronal firing.

• Secondary mechanism: Ion channel dysfunction plays a critical role, often involving sodium, potassium, or calcium channels. Mutations or alterations in these channels can disrupt normal neuronal signaling and contribute to the hyperexcitability that underlies seizure activity.

• Key complication: Repeated or prolonged seizures can lead to neuronal injury and structural brain changes, potentially resulting in cognitive impairments and increased susceptibility to further seizures, known as epileptogenesis.

Patient Profile

Demographics:

32-year-old female, software engineer

History:

• Key past medical history: Epilepsy diagnosed 5 years ago, with occasional breakthrough seizures despite medication

• Current medications: Lamotrigine 200 mg twice daily, Levothyroxine 50 mcg daily

• Allergies: Penicillin

Current Presentation:

• Chief complaint: Increased frequency of seizures over the past week

• Key symptoms: Generalized tonic-clonic seizures occurring twice in the past 24 hours, confusion post-seizure, mild headache, fatigue

• Vital signs: Blood pressure 145/90 mmHg, heart rate 110 bpm, respiratory rate 20 breaths per minute, temperature 37.5°C, oxygen saturation 93% on room air

Section 1

As the healthcare team continues to monitor the patient, new diagnostic results provide additional insight into her condition. An EEG conducted during her hospital stay reveals increased epileptiform activity, particularly in the temporal lobes, correlating with the recent uptick in seizure frequency. MRI results indicate subtle changes in the hippocampal region, suggesting the possibility of hippocampal sclerosis, a common finding in patients with temporal lobe epilepsy. These findings raise concerns about potential progression of her epilepsy and the risk of developing drug-resistant seizures.

Concurrently, laboratory tests show a slight decrease in serum sodium levels at 132 mmol/L, which may contribute to neuronal excitability and could partially explain the increased seizure activity. This hyponatremia prompts the healthcare team to review her medication regimen, recognizing that while lamotrigine is effective, it may need to be adjusted or supplemented with additional antiepileptic drugs to better control her seizures. Moreover, thyroid function tests reveal that her TSH levels are slightly elevated, suggesting suboptimal control of her hypothyroidism, which could contribute to her fatigue and possibly exacerbate seizure activity.

In response to these findings, the interdisciplinary team initiates a plan to address the identified issues. They consider adjusting her lamotrigine dosage and explore the addition of another anticonvulsant, such as levetiracetam, to enhance seizure control. Additionally, they propose a cautious correction of her sodium levels to prevent further complications. These changes are aimed at stabilizing her condition and reducing the frequency of seizures, while also addressing her thyroid dysfunction to improve her overall well-being. This multifaceted approach highlights the need for ongoing assessment and collaborative management to prevent further complications and optimize patient outcomes.

Section 2

As the healthcare team implements the adjusted treatment plan, the patient initially shows some positive response to the interventions. Her serum sodium levels begin to stabilize after careful management with a controlled infusion of hypertonic saline, now measuring at 135 mmol/L, which is within the normal range. This correction helps reduce the neuronal excitability associated with her hyponatremia. Additionally, the introduction of levetiracetam alongside lamotrigine appears to contribute to a reduction in seizure frequency, with no episodes reported in the first 48 hours following the medication adjustment.

However, during the subsequent monitoring period, the patient begins to exhibit signs of cognitive changes, such as mild confusion and memory lapses, which raise concerns for the healthcare team. Her vital signs remain stable with a blood pressure of 118/76 mmHg, heart rate of 82 beats per minute, and oxygen saturation at 98% on room air, yet her mental status changes necessitate further investigation. Repeat MRI scans do not show acute changes, but the subtle hippocampal sclerosis noted earlier suggests potential chronic changes that could impact her cognitive function.

These developments prompt the team to engage in a deeper clinical reasoning process, evaluating the possibility of levetiracetam-induced cognitive side effects or progression of hippocampal sclerosis contributing to her symptoms. The team discusses the balance between seizure control and the patient’s cognitive function, considering alternative options such as adjusting the dosage of levetiracetam or exploring other antiepileptic medications. The need for regular cognitive assessments and close monitoring becomes a priority to ensure the patient's safety and quality of life, while also coordinating with neurology and psychiatry specialists to refine the treatment plan. This situation underscores the complexity of managing epilepsy with potential comorbidities, highlighting the importance of personalized care and the need to anticipate and address new challenges as they arise.

Section 3

As the healthcare team continues to monitor the patient closely, they decide to perform a comprehensive neurocognitive assessment to further evaluate her cognitive changes. The assessment reveals that the patient is experiencing increased difficulty with short-term memory retention and attention span, which appear to be more pronounced than previously observed. Additionally, there are intermittent episodes of disorientation where the patient struggles to recognize familiar healthcare staff. These findings raise concerns about the potential cognitive side effects of levetiracetam, leading the team to consult with a neurologist to determine the best course of action.

In parallel, a thorough review of the patient's current medication regimen and recent lab results is conducted. Her complete blood count and metabolic panel remain within normal ranges, ruling out common metabolic causes for her cognitive changes. However, the serum level of levetiracetam is noted to be on the higher end of the therapeutic range, suggesting the possibility of drug-related cognitive impairment. Given this, the team considers a cautious reduction in the levetiracetam dosage while maintaining seizure control, potentially by optimizing lamotrigine levels or introducing an alternative antiepileptic drug with a more favorable cognitive profile.

As adjustments to the treatment plan are made, the patient's condition is monitored closely for both seizure activity and cognitive function. Regular follow-up assessments are scheduled to evaluate the impact of these changes, ensuring that any further decline in cognitive status can be addressed promptly. The involvement of a multidisciplinary team, including neurology, psychiatry, and pharmacy, becomes crucial in balancing the complex interplay of seizure management and cognitive well-being, reinforcing the need for a holistic and adaptive approach to her care.

Section 4

As the multidisciplinary team implements the adjusted treatment plan, a series of follow-up assessments reveal notable changes in the patient's condition. Within a week of reducing the levetiracetam dosage and optimizing lamotrigine levels, the patient exhibits a slight improvement in cognitive function. Her attention span shows modest enhancement, and episodes of disorientation have decreased in frequency, indicating a positive response to the medication adjustments. However, the team remains vigilant as the patient reports experiencing mild headaches and occasional dizziness, symptoms that warrant close observation to ensure they do not signify an underlying complication.

Despite these improvements, a new complication emerges when the patient experiences a breakthrough seizure, characterized by a generalized tonic-clonic episode lasting approximately two minutes. Vital signs post-seizure reveal a transient increase in blood pressure to 150/95 mmHg and a heart rate of 110 bpm, which gradually normalize with supportive care. The breakthrough seizure prompts the team to reevaluate the balance between cognitive function and seizure control. Detailed discussions with the neurologist lead to the decision to introduce a low-dose of topiramate, chosen for its potential cognitive benefits and effectiveness in seizure management.

The introduction of topiramate is conducted with careful titration, and the patient is closely monitored for any adverse effects or further cognitive changes. Subsequent neurocognitive assessments are scheduled to track her progress, with the team prepared to make further adjustments as needed. This unfolding situation underscores the complexity of managing epilepsy in the context of cognitive side effects, highlighting the necessity for ongoing clinical reasoning and adaptive strategies in the patient's care plan.

Section 5

As the multidisciplinary team continues to manage the patient's treatment, a change in her status becomes evident. Within two weeks of introducing topiramate, the patient reports experiencing tingling sensations in her fingers and toes, a known side effect of the medication. Additionally, her family notes a subtle increase in her irritability and a slight decline in her verbal fluency, which raises concerns about the cognitive impact of the new drug regimen. The team conducts a thorough assessment, noting that her vital signs remain stable with a blood pressure of 135/85 mmHg and a heart rate of 78 bpm. However, blood tests reveal a mild metabolic acidosis, with a bicarbonate level of 20 mmol/L, suggesting a possible side effect of the topiramate.

In response to these developments, the team engages in detailed discussions regarding the risk-benefit ratio of continuing topiramate. The neurologist suggests a slight reduction in the dosage to mitigate the side effects while maintaining seizure control. The team also explores non-pharmacological interventions to support cognitive function, such as cognitive behavioral therapy and structured activities to enhance verbal skills. The patient's progress is closely monitored, with plans for frequent follow-up appointments to track any further changes in her condition. This evolving situation highlights the need for careful balancing of therapeutic goals, emphasizing the importance of individualized care plans and the adaptability required in managing complex cases.